RCKT — Rocket Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $251.38m
- -$11.09m
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08
Brief: Rocket Pharmaceuticals Announces Positive Clinical Safety Update From Initial Three Patients Treated With Rp-A501 Under Modified Phase 2 Protocol For Danon Disease
Rocket Pharmaceuticals Inc expected to post earnings of 37 cents a share - Earnings Preview
Brief: Rocket Pharmaceuticals Announces Closing Of Sale Of Rare Pediatric Disease Priority Review Voucher For $180 Million
Rocket Pharmaceuticals Q1 net loss narrows on lower expenses
US FDA's accelerated approval for drugs needs more transparency, says research firm (updated)
US FDA's accelerated approval for drugs needs more transparency, says research firm
Brief: FDA Issuance Of A Priority Review Voucher To The Sponsor Of A Rare Pediatric Disease Product Application- Federal Register Website
U.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
Rocket Pharma shares fall despite FDA nod for childhood disorder treatment (updated)
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
Rocket Pharma rises after FDA approves gene therapy for fatal childhood disorder
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
Rocket Pharmaceuticals Q3 net loss narrows
U.S. STOCKS ON THE MOVE-Occidental Petroleum , GameStop, Alphabet